Medications for Weight Reduction

被引:15
作者
Bray, George A. [1 ]
机构
[1] Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA
关键词
Sympathomimetic drugs; Lipase inhibitor; Cannabinoid receptor antagonists; Glucagon-like peptide analogues;
D O I
10.1016/j.ecl.2008.08.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Only two drugs are currently approved for long-term use in the treatment of obesity and four others for short-term use. Evaluating the risk-benefit profile is an essential first step. For individuals who have a low body mass index for whom the risk is small, the risk profile must make the drug acceptable for almost everyone. For higher-risk patients, such as those planning intestinal bypass or who have sleep apnea, a wider range of drugs may be considered. Obesity is a chronic disease that has many causes. Treatment is aimed at palliation-that is, producing and maintaining weight loss. Regardless of the primary site of action, the net effect must be a reduction in food intake or increase in energy expenditure.
引用
收藏
页码:923 / +
页数:21
相关论文
共 88 条
[61]   Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials [J].
Padwal, R ;
Li, SK ;
Lau, DCW .
INTERNATIONAL JOURNAL OF OBESITY, 2003, 27 (12) :1437-1446
[62]   Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status [J].
Parker, E ;
Van Heek, M ;
Stamford, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 440 (2-3) :173-187
[63]   The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery [J].
Patriti, A ;
Facchiano, E ;
Sanna, A ;
Gullà, N ;
Donini, A .
OBESITY SURGERY, 2004, 14 (06) :840-848
[64]   Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: A randomized controlled trial [J].
Pi-Sunyer, F ;
Aronne, LJ ;
Heshmati, HM ;
Devin, J ;
Rosenstock, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (07) :761-775
[65]  
Pi-Sunyer FX, 1998, OBES RES, V6, p51S
[66]   Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial [J].
Ratner, RE ;
Dickey, R ;
Fineman, M ;
Maggs, DG ;
Shen, L ;
Strobel, SA ;
Weyer, C ;
Kolterman, OG .
DIABETIC MEDICINE, 2004, 21 (11) :1204-1212
[67]   Lack of an effect of a novel β3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals:: A double-blind, placebo-controlled randomized study [J].
Redman, Leanne M. ;
de Jonge, Lilian ;
Fang, Xiaobing ;
Gamlin, Betsy ;
Recker, David ;
Greenway, Frank L. ;
Smith, Steven R. ;
Ravussin, Eric .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (02) :527-531
[68]   Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1 [J].
Riddle, MC ;
Drucker, DJ .
DIABETES CARE, 2006, 29 (02) :435-449
[69]   EFFECT OF ANOREXIC DRUGS ON FOOD-INTAKE AND THE MICROSTRUCTURE OF EATING IN HUMAN-SUBJECTS [J].
ROGERS, PJ ;
BLUNDELL, JE .
PSYCHOPHARMACOLOGY, 1979, 66 (02) :159-165
[70]   Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study [J].
Scheen, Andre J. ;
Finer, Nick ;
Hollander, Priscilla ;
Jensen, Michael D. ;
Van Gaal, Luc F. .
LANCET, 2006, 368 (9548) :1660-1672